• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

达沙替尼——伊马替尼耐药/不耐受慢性髓性白血病的临床试验及不良事件管理

Dasatinib - clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia.

作者信息

Conchon Monika, Freitas Carla Maria Boquimpani de Moura, Rego Maria Aparecida do Carmo, Braga Junior José Wilson Ramos

机构信息

Hematology Service, Hospital Santa Marcelina, São Paulo, SP, Brazil.

出版信息

Rev Bras Hematol Hemoter. 2011;33(2):131-9. doi: 10.5581/1516-8484.20110034.

DOI:10.5581/1516-8484.20110034
PMID:23284261
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3520638/
Abstract

Dasatinib is a highly effective second generation tyrosine kinase inhibitor approved for the treatment of imatinib-resistant or intolerant chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia. This article reviews the results of phase I, II and III studies and looks at the efficacy and safety of dasatinib. This review also provides practical recommendations for the management of side effects.

摘要

达沙替尼是一种高效的第二代酪氨酸激酶抑制剂，被批准用于治疗对伊马替尼耐药或不耐受的慢性髓性白血病以及费城染色体阳性的急性淋巴细胞白血病。本文回顾了I期、II期和III期研究的结果，并探讨了达沙替尼的疗效和安全性。本综述还为副作用的管理提供了实用建议。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9fb1/3520638/9c20f87b4d68/rbhh-33-131-g04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9fb1/3520638/dc14a367be20/rbhh-33-131-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9fb1/3520638/d5606912593b/rbhh-33-131-g02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9fb1/3520638/4ac53200f98d/rbhh-33-131-g03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9fb1/3520638/9c20f87b4d68/rbhh-33-131-g04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9fb1/3520638/dc14a367be20/rbhh-33-131-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9fb1/3520638/d5606912593b/rbhh-33-131-g02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9fb1/3520638/4ac53200f98d/rbhh-33-131-g03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9fb1/3520638/9c20f87b4d68/rbhh-33-131-g04.jpg

相似文献

1
Dasatinib - clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia.达沙替尼——伊马替尼耐药/不耐受慢性髓性白血病的临床试验及不良事件管理
Rev Bras Hematol Hemoter. 2011;33(2):131-9. doi: 10.5581/1516-8484.20110034.
2
Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.达沙替尼：一种用于治疗慢性粒细胞白血病和费城染色体阳性急性淋巴细胞白血病的酪氨酸激酶抑制剂。
Clin Ther. 2007 Nov;29(11):2289-308. doi: 10.1016/j.clinthera.2007.11.005.
3
Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia.达沙替尼：用于治疗慢性髓性白血病和费城染色体阳性急性淋巴细胞白血病的综述。
Drugs. 2011 Sep 10;71(13):1771-95. doi: 10.2165/11207580-000000000-00000.
4
Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.达沙替尼：从治疗对伊马替尼耐药或不耐受的慢性髓性白血病患者到治疗新诊断的慢性期慢性髓性白血病患者。
Clin Ther. 2012 Feb;34(2):272-81. doi: 10.1016/j.clinthera.2012.01.009. Epub 2012 Jan 27.
5
Spotlight on dasatinib in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.聚焦达沙替尼在慢性髓性白血病和费城染色体阳性急性淋巴细胞白血病中的应用。
BioDrugs. 2012 Feb 1;26(1):61-4. doi: 10.2165/11207640-000000000-00000.
6
Efficacy of molecular response at 1 or 3 months after the initiation of dasatinib treatment can predict an improved response to dasatinib in imatinib-resistant or imatinib-intolerant Japanese patients with chronic myelogenous leukemia during the chronic phase.达沙替尼治疗开始后1个月或3个月时的分子反应疗效，可预测慢性期伊马替尼耐药或不耐受的日本慢性粒细胞白血病患者对达沙替尼的反应改善情况。
J Clin Exp Hematop. 2014;54(3):197-204. doi: 10.3960/jslrt.54.197.
7
Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.达沙替尼在伊马替尼治疗失败后的慢性期慢性髓性白血病中可诱导显著的血液学和细胞遗传学反应。
Blood. 2007 Mar 15;109(6):2303-9. doi: 10.1182/blood-2006-09-047266. Epub 2006 Nov 30.
8
Dasatinib: in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.达沙替尼：用于慢性粒细胞白血病和费城染色体阳性的急性淋巴细胞白血病。
BioDrugs. 2008;22(1):59-69. doi: 10.2165/00063030-200822010-00007.
9
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.达沙替尼可使对伊马替尼耐药或不耐受的慢性期慢性髓性白血病患者产生持久的细胞遗传学反应。
Leukemia. 2008 Jun;22(6):1200-6. doi: 10.1038/leu.2008.84. Epub 2008 Apr 10.
10
Dasatinib.达沙替尼
Drugs Today (Barc). 2007 Jan;43(1):5-12. doi: 10.1358/dot.2007.43.1.1050791.

引用本文的文献

1
Identification of new dasatinib analogues targeting mutated BCR-ABL1: virtual screening, molecular docking, and dynamics simulations studies.鉴定靶向突变型BCR-ABL1的新型达沙替尼类似物：虚拟筛选、分子对接和动力学模拟研究
Mol Divers. 2025 Aug 9. doi: 10.1007/s11030-025-11310-7.
2
Current and future of targeted therapies against BCR::ABL kinases.针对BCR::ABL激酶的靶向治疗的现状与未来。
J Egypt Natl Canc Inst. 2025 Apr 7;37(1):12. doi: 10.1186/s43046-025-00263-5.
3
Role of dasatinib in the management of lung cancer: A meta-analysis of clinical trials.

本文引用的文献

1
The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib.TKI 治疗相关 CML 液体潴留的发生和管理，重点是达沙替尼。
J Hematol Oncol. 2009 Nov 12;2:46. doi: 10.1186/1756-8722-2-46.
2
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R).达沙替尼或高剂量伊马替尼用于对每日400至600毫克剂量伊马替尼耐药的慢性期慢性髓性白血病：一项随机2期研究（START-R）的两年随访
Cancer. 2009 Sep 15;115(18):4136-47. doi: 10.1002/cncr.24504.
3
Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial.
达沙替尼在肺癌治疗中的作用：一项临床试验的荟萃分析。
Biomed Rep. 2025 Jan 23;22(3):51. doi: 10.3892/br.2025.1929. eCollection 2025 Mar.
4
The tobacco-specific carcinogen NNK induces pulmonary tumorigenesis via nAChR/Src/STAT3-mediated activation of the renin-angiotensin system and IGF-1R signaling.烟草特异性致癌原 NNK 通过烟碱型乙酰胆碱受体/原癌基因Src/信号转导与转录激活因子 3 介导的肾素-血管紧张素系统和胰岛素样生长因子 1 受体信号通路诱导肺肿瘤发生。
Exp Mol Med. 2023 Jun;55(6):1131-1144. doi: 10.1038/s12276-023-00994-2. Epub 2023 Jun 1.
5
Exploring the chemotherapeutic potential of currently used kinase inhibitors: An update.探索当前使用的激酶抑制剂的化疗潜力：最新进展。
Front Pharmacol. 2023 Jan 9;13:1064472. doi: 10.3389/fphar.2022.1064472. eCollection 2022.
6
Molecular targeted therapy for anticancer treatment.用于抗癌治疗的分子靶向治疗。
Exp Mol Med. 2022 Oct;54(10):1670-1694. doi: 10.1038/s12276-022-00864-3. Epub 2022 Oct 12.
7
A rare case of B-lymphoid blast phase of chronic myeloid leukemia: Diagnostic challenges.慢性髓性白血病B淋巴细胞母细胞期1例罕见病例：诊断挑战
Leuk Res Rep. 2022 May 20;17:100327. doi: 10.1016/j.lrr.2022.100327. eCollection 2022.
8
E-Cadherin-Deficient Cells Are Sensitive to the Multikinase Inhibitor Dasatinib.E-钙黏蛋白缺陷型细胞对多激酶抑制剂达沙替尼敏感。
Cancers (Basel). 2022 Mar 22;14(7):1609. doi: 10.3390/cancers14071609.
9
Senolytics: A Novel Strategy for Neuroprotection in ALS?衰老细胞清除剂：ALS 神经保护的新策略？
Int J Mol Sci. 2021 Nov 8;22(21):12078. doi: 10.3390/ijms222112078.
10
Engineering Next-Generation CAR-T Cells for Better Toxicity Management.工程化下一代 CAR-T 细胞以更好地进行毒性管理。
Int J Mol Sci. 2020 Nov 16;21(22):8620. doi: 10.3390/ijms21228620.
达沙替尼用于治疗伊马替尼治疗失败后的加速期慢性髓性白血病：START a试验
J Clin Oncol. 2009 Jul 20;27(21):3472-9. doi: 10.1200/JCO.2007.14.3339. Epub 2009 Jun 1.
4
Pharmacoeconomic benefits of dasatinib in the treatment of imatinib-resistant patients with chronic myelogenous leukemia.达沙替尼治疗伊马替尼耐药慢性髓性白血病患者的药物经济学效益
Expert Rev Pharmacoecon Outcomes Res. 2009 Apr;9(2):117-21. doi: 10.1586/erp.09.1.
5
Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up.达沙替尼140毫克每日一次与70毫克每日两次用于对伊马替尼耐药或不耐受的加速期慢性髓性白血病患者的3期研究：15个月中位随访
Blood. 2009 Jun 18;113(25):6322-9. doi: 10.1182/blood-2008-11-186817. Epub 2009 Apr 15.
6
New dosing schedules of dasatinib for CML and adverse event management.达沙替尼治疗 CML 的新剂量方案和不良反应管理。
J Hematol Oncol. 2009 Feb 23;2:10. doi: 10.1186/1756-8722-2-10.
7
Dasatinib treatment for Philadelphia chromosome-positive leukemias: practical considerations.达沙替尼治疗费城染色体阳性白血病：实际考量
Cancer. 2009 Apr 1;115(7):1381-94. doi: 10.1002/cncr.24155.
8
Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.达沙替尼治疗处于急变期的伊马替尼耐药或不耐受慢性髓性白血病患者的疗效与安全性。
Leukemia. 2008 Dec;22(12):2176-83. doi: 10.1038/leu.2008.221. Epub 2008 Aug 28.
9
Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia.每日一次服用100毫克达沙替尼进行间歇性靶向抑制可维持疗效，并提高对伊马替尼耐药和不耐受的慢性期慢性髓性白血病患者的耐受性。
J Clin Oncol. 2008 Jul 1;26(19):3204-12. doi: 10.1200/JCO.2007.14.9260. Epub 2008 Jun 9.
10
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.达沙替尼可使对伊马替尼耐药或不耐受的慢性期慢性髓性白血病患者产生持久的细胞遗传学反应。
Leukemia. 2008 Jun;22(6):1200-6. doi: 10.1038/leu.2008.84. Epub 2008 Apr 10.